{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:06:19Z","timestamp":1784214379488,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["D43TW009771"],"award-info":[{"award-number":["D43TW009771"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-3907-5","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T13:02:41Z","timestamp":1553518961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7937-1538","authenticated-orcid":false,"given":"Eva Agnes Odongpiny","family":"Laker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sarah","family":"Nabaggala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Kaimal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damalie","family":"Nalwanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdu","family":"Musubire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Kiragga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Lamorde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind Parkes-","family":"Ratanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,25]]},"reference":[{"key":"3907_CR1","unstructured":"Joint United Nations Programme on HIV\/AIDS. Global AIDS Update 2016. http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/global-AIDS-update-2016_en.pdf . Accessed 10 Jan 2018."},{"issue":"8","key":"3907_CR2","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1097\/QAD.0b013e328351f5b2","volume":"26","author":"O Ajose","year":"2012","unstructured":"Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012;26(8):929\u201338.","journal-title":"AIDS."},{"key":"3907_CR3","unstructured":"World Health Organisation. Global report: UNAIDS report on the global AIDS epidemic 2013. http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_Global_Report_2013_en_1.pdf. UNAIDS;2013 . Accessed 15 Dec 2016."},{"issue":"12","key":"3907_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082724","volume":"8","author":"Y Madec","year":"2013","unstructured":"Madec Y, Leroy S, Rey-Cuille MA, Huber F, Calmy A. Persistent difficulties in switching to second-line ART in sub-saharan Africa--a systematic review and meta-analysis. PLoS One. 2013;8(12):e82724.","journal-title":"PLoS One"},{"key":"3907_CR5","doi-asserted-by":"crossref","unstructured":"Somnuek Sungkanuparph WM, 2 Sasisopin Kiertiburanakul,1 Bucha Piyavong,1, Noppanath Chumpathat WC. Options for a Second-Line Antiretroviral Regimen for HIV Type 1\u2013Infected Patients Whose Initial Regimenof a Fixed-Dose Combination of Stavudine,Lamivudine, and Nevirapine Fails. Clin Infect Dis. 2007;44(3):447\u201352.","DOI":"10.1086\/510745"},{"key":"3907_CR6","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infcetion. .Recommendations for a public health approach. 2013. http:\/\/apps.who.int\/iris\/bitstream\/10665\/85321\/1\/9789241505727_eng.pdf?ua=1 Accessed 28 May 2017."},{"key":"3907_CR7","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection.Recommendations for a public health approach - Second edition. 2016. http:\/\/apps.who.int\/iris\/bitstream\/10665\/208825\/1\/9789241549684_eng.pdf?ua=1 . Accessed 22 Dec 2017."},{"key":"3907_CR8","doi-asserted-by":"crossref","unstructured":"Sigaloff KC, Hamers R, Wallis CL, Kityo C, et al Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011;58(1):23\u201331.","DOI":"10.1097\/QAI.0b013e318227fc34"},{"issue":"8","key":"3907_CR9","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S2352-3018(17)30065-6","volume":"4","author":"NI Paton","year":"2017","unstructured":"Paton NI, Kityo C, Thompson J, et al. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. Lancet HIV. 2017;4(8):e341\u20138.","journal-title":"Lancet HIV"},{"key":"3907_CR10","doi-asserted-by":"crossref","unstructured":"Hosseinipour MC, van Oosterhout JJG ,Weigel R, Phiri S, et al. the public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009;23(9):1127\u201334.","DOI":"10.1097\/QAD.0b013e32832ac34e"},{"key":"3907_CR11","unstructured":"Molina JM, Andrade-Villanueva J,Echevarria J, Chetchotisakd P, et al. Once-daily atazanavir\/ritonavir compared with twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. Lancet Mar 2008;53(3):323\u2013332."},{"key":"3907_CR12","doi-asserted-by":"crossref","unstructured":"Fernandez-Montero JV, Barreiro P, Soriano V. HIV protease inhibitors: recent clinical trials and recommendations on use. Expert Opin Pharmacother Jul 15 2009;10(10):1615\u20131629.","DOI":"10.1517\/14656560902980202"},{"key":"3907_CR13","doi-asserted-by":"crossref","unstructured":"Hirsch MS, Gunthard Hf, Schapiro JM, Brun-Vezinet F, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an international AIDS society-USA panel. Clin Infec DisJul 15 2008; 47(2): 266\u2013285.","DOI":"10.1086\/589297"},{"key":"3907_CR14","unstructured":"WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a Public Health approach.\u2013 2010 revision. 2010. http:\/\/apps.who.int\/iris\/bitstream\/10665\/44379\/1\/9789241599764_eng.pdf . Accessed 20 Jul 2017."},{"key":"3907_CR15","volume-title":"Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. \u2013 2006 revision","author":"World Health Organisation","year":"2006","unstructured":"World Health Organisation. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. \u2013 2006 revision. 2006."},{"key":"3907_CR16","unstructured":"World Health Organisation. Scaling up Antiretroviral Therapy in Resource -Limited Settings: Treatment Guidelines for A public Health Approach. 2003.\u00a0 https:\/\/www.who.int\/hiv\/pub\/prev_care\/en\/arvrevision2003en.pdf?ua=1 . Accessed 20 Jul 2017."},{"key":"3907_CR17","unstructured":"17th Expert Committee on the Selection and Use of Essential Medicines, Geneva. Application for the listing of Atazanvir for the treatment of HIV-1 infection on the WHO model list of essential medicines Feb 2009. http:\/\/www.who.int\/selection_medicines\/committees\/expert\/17\/application\/Atazanavir.pdf . Accessed 1 Nov 2017."},{"key":"3907_CR18","unstructured":"WHO. What ARV regimen to switch to in adults, pregnant women, Adolescents and children living with HIV (once-daily PI regimens)? 2013. http:\/\/apps.who.int\/iris\/bitstream\/10665\/90773\/1\/WHO_HIV_2013.38_eng.pdf . Accessed 15 May 2017."},{"key":"3907_CR19","volume-title":"Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovirand emtricitabine, For management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety resultsof the CASTLE study","author":"JA-V Jean-Michel Molina","year":"2008","unstructured":"Jean-Michel Molina JA-V, Juan Echevarria, Ploenchan Chetchotisakd, Jorge Corral, Neal David, Graeme Moyle, Marco Mancini LP, Rong Yang, Alexandra Thiry, Donnie McGrath, for the CASTLE study team*. Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovirand emtricitabine, For management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety resultsof the CASTLE study. 2008."},{"key":"3907_CR20","volume-title":"The integrated National Guidelines on antiretroviral therapy, Prevention of mother to child transmission of HIV and Infant & Young Child Feeding","author":"The Republic of Uganda MoH","year":"2011","unstructured":"The Republic of Uganda MoH. The integrated National Guidelines on antiretroviral therapy, Prevention of mother to child transmission of HIV and Infant & Young Child Feeding. 1st ed; 2011.","edition":"1"},{"issue":"2","key":"3907_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3851\/IMP2815","volume":"20","author":"N Boillat-Blanco","year":"2015","unstructured":"Boillat-Blanco N, Darling KE, Schoni-Affolter F, Vuichard D, Rougemont M, Fulchini R, et al. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV cohort study. Antivir Ther. 2015;20(2):165\u201375.","journal-title":"Antivir Ther"},{"issue":"3","key":"3907_CR22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/QAD.0000000000000544","volume":"29","author":"MA Vandenhende","year":"2015","unstructured":"Vandenhende MA, Ingle S, May M, Chene G, Zangerle R, Van Sighem A, et al. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS (London, England). 2015;29(3):373\u201383.","journal-title":"AIDS (London, England)"},{"key":"3907_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1742-6405-11-18","volume":"11","author":"N Chkhartishvili","year":"2014","unstructured":"Chkhartishvili N, Sharvadze L, Dvali N, et al. Virologic outcomes of second-line antiretroviral therapy in eastern European country of Georgia. AIDS Res Ther. 2014;11:18.","journal-title":"AIDS Res Ther"},{"key":"3907_CR24","unstructured":"Johnson M, Grinsztejn B , Rodriguez C , Coco J, et al. 96-week comparison of once-daily atazanavir\/ritonavir and twice-daily lopinavir\/ritonavir in patients with multiple virologic failures. AIDS. Mar 21 2006;20(5):711\u2013718."},{"key":"3907_CR25","unstructured":"Ciaffia L, Koulla-Shirob S, Sawadogo A, et al. Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa. AIDS. Jul 31 2015;29(12): 1473\u20131481."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3907-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-3907-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3907-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T09:15:39Z","timestamp":1663146939000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-3907-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,25]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3907"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-3907-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,25]]},"assertion":[{"value":"27 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All routinely collected clinic data is approved for analysis and reporting by the Makerere University Faculty of Medicine, Research and Ethics committee (approval number: 120\u20132009) and Uganda National Council for Science and Technology (approval number: 45683) hence the need for consent was waived by an IRB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"280"}}